325 related articles for article (PubMed ID: 18316486)
1. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.
Kontaridis MI; Yang W; Bence KK; Cullen D; Wang B; Bodyak N; Ke Q; Hinek A; Kang PM; Liao R; Neel BG
Circulation; 2008 Mar; 117(11):1423-35. PubMed ID: 18316486
[TBL] [Abstract][Full Text] [Related]
2. LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.
Ishida H; Kogaki S; Narita J; Ichimori H; Nawa N; Okada Y; Takahashi K; Ozono K
Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1531-9. PubMed ID: 21803945
[TBL] [Abstract][Full Text] [Related]
3. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
Schramm C; Edwards MA; Krenz M
J Biol Chem; 2013 Jun; 288(25):18335-44. PubMed ID: 23673659
[TBL] [Abstract][Full Text] [Related]
4. Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.
Krenz M; Yutzey KE; Robbins J
Circ Res; 2005 Oct; 97(8):813-20. PubMed ID: 16166557
[TBL] [Abstract][Full Text] [Related]
5. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
Bonetti M; Paardekooper Overman J; Tessadori F; Noël E; Bakkers J; den Hertog J
Development; 2014 May; 141(9):1961-70. PubMed ID: 24718990
[TBL] [Abstract][Full Text] [Related]
6. Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.
Jopling C; van Geemen D; den Hertog J
PLoS Genet; 2007 Dec; 3(12):e225. PubMed ID: 18159945
[TBL] [Abstract][Full Text] [Related]
7. SHP2 mediates gp130-dependent cardiomyocyte hypertrophy via negative regulation of skeletal alpha-actin gene.
Nakaoka Y; Shioyama W; Kunimoto S; Arita Y; Higuchi K; Yamamoto K; Fujio Y; Nishida K; Kuroda T; Hirota H; Yamauchi-Takihara K; Hirano T; Komuro I; Mochizuki N
J Mol Cell Cardiol; 2010 Aug; 49(2):157-64. PubMed ID: 20226789
[TBL] [Abstract][Full Text] [Related]
8. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
9. Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome.
Nakamura T; Colbert M; Krenz M; Molkentin JD; Hahn HS; Dorn GW; Robbins J
J Clin Invest; 2007 Aug; 117(8):2123-32. PubMed ID: 17641779
[TBL] [Abstract][Full Text] [Related]
10. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
Schramm C; Fine DM; Edwards MA; Reeb AN; Krenz M
Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H231-43. PubMed ID: 22058153
[TBL] [Abstract][Full Text] [Related]
11. Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome.
Krenz M; Gulick J; Osinska HE; Colbert MC; Molkentin JD; Robbins J
Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18930-5. PubMed ID: 19017799
[TBL] [Abstract][Full Text] [Related]
12. Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines.
Yi JS; Perla S; Enyenihi L; Bennett AM
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32584792
[TBL] [Abstract][Full Text] [Related]
13. Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines.
Roy R; Krenz M
J Mol Cell Cardiol; 2017 Nov; 112():83-90. PubMed ID: 28911943
[TBL] [Abstract][Full Text] [Related]
14. Deletion of Shp2 tyrosine phosphatase in muscle leads to dilated cardiomyopathy, insulin resistance, and premature death.
Princen F; Bard E; Sheikh F; Zhang SS; Wang J; Zago WM; Wu D; Trelles RD; Bailly-Maitre B; Kahn CR; Chen Y; Reed JC; Tong GG; Mercola M; Chen J; Feng GS
Mol Cell Biol; 2009 Jan; 29(2):378-88. PubMed ID: 19001090
[TBL] [Abstract][Full Text] [Related]
15. RhoA signaling in cardiomyocytes protects against stress-induced heart failure but facilitates cardiac fibrosis.
Lauriol J; Keith K; Jaffré F; Couvillon A; Saci A; Goonasekera SA; McCarthy JR; Kessinger CW; Wang J; Ke Q; Kang PM; Molkentin JD; Carpenter C; Kontaridis MI
Sci Signal; 2014 Oct; 7(348):ra100. PubMed ID: 25336613
[TBL] [Abstract][Full Text] [Related]
16. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
[TBL] [Abstract][Full Text] [Related]
17. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
De Rocca Serra-Nédélec A; Edouard T; Tréguer K; Tajan M; Araki T; Dance M; Mus M; Montagner A; Tauber M; Salles JP; Valet P; Neel BG; Raynal P; Yart A
Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4257-62. PubMed ID: 22371576
[TBL] [Abstract][Full Text] [Related]
18. FasL expression in cardiomyocytes activates the ERK1/2 pathway, leading to dilated cardiomyopathy and advanced heart failure.
Huby AC; Turdi S; James J; Towbin JA; Purevjav E
Clin Sci (Lond); 2016 Feb; 130(4):289-99. PubMed ID: 26566650
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.
Yu ZH; Zhang RY; Walls CD; Chen L; Zhang S; Wu L; Liu S; Zhang ZY
Biochemistry; 2014 Jul; 53(25):4136-51. PubMed ID: 24935154
[TBL] [Abstract][Full Text] [Related]
20. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.
Marin TM; Clemente CF; Santos AM; Picardi PK; Pascoal VD; Lopes-Cendes I; Saad MJ; Franchini KG
Circ Res; 2008 Oct; 103(8):813-24. PubMed ID: 18757826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
